Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its price target lifted by HC Wainwright from $6.00 to $7.00 in a research note published on Tuesday morning, The Fly reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, August 16th. Needham & Company LLC reissued a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Friday, August 3rd. Finally, ValuEngine lowered shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 30th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Tetraphase Pharmaceuticals presently has an average rating of Hold and an average target price of $6.28.

Shares of TTPH opened at $3.42 on Tuesday. The stock has a market capitalization of $180.39 million, a PE ratio of -1.30 and a beta of 2.44. Tetraphase Pharmaceuticals has a fifty-two week low of $2.05 and a fifty-two week high of $7.98.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. The company had revenue of $11.58 million for the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 421.64% and a negative return on equity of 67.34%. sell-side analysts predict that Tetraphase Pharmaceuticals will post -1.37 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in TTPH. Flagship Harbor Advisors LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at about $104,000. Cubist Systematic Strategies LLC grew its stake in shares of Tetraphase Pharmaceuticals by 232.1% in the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 24,837 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at about $179,000. Dynamic Technology Lab Private Ltd grew its stake in shares of Tetraphase Pharmaceuticals by 322.1% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 58,079 shares in the last quarter. Finally, Alambic Investment Management L.P. acquired a new position in shares of Tetraphase Pharmaceuticals in the first quarter valued at about $356,000. Institutional investors and hedge funds own 40.94% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Article: Trading Strategy Examples and Plans

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.